BIBLIOGRAFÍA CÁNCER DE PULMÓN: INTRODUCCIÓN Y CASOS CLÍNICOS 1 Y 2

​

1.         Arita T, Kuramitsu T, Kawamura M, Matsumoto T, Matsunaga N, Sugi K, et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax [Internet]. 1995 Dec [cited 2019 Jan 20];50(12):1267–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8553299

2.         Chin R, Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt S, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2090–6.

3.         Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial. J Thorac Oncol [Internet]. 2011 Aug [cited 2019 Jan 20];6(8):1367–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21587082

4.         Defranchi SA, Edell ES, Daniels CE, Prakash UBS, Swanson KL, Utz JP, et al. Mediastinoscopy in Patients With Lung Cancer and Negative Endobronchial Ultrasound Guided Needle Aspiration. Ann Thorac Surg [Internet]. 2010 Dec [cited 2019 Jan 20];90(6):1753–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21095301

5.         Koshy M, Fedewa SA, Malik R, Ferguson MK, Vigneswaran WT, Feldman L, Howard A, Abdelhady K, Weichselbaum RR VK. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer. J Thorac Oncol. 2013;8(7):915–22.

6.         Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane database Syst Rev [Internet]. 2007 Jul 18 [cited 2019 Feb 21];(3):CD006157. Available from: http://doi.wiley.com/10.1002/14651858.CD006157.pub2

7.         Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT CJ. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–86.

8.         Couñago F, Rodriguez de Dios N, Montemuiño S, Jové-Teixidó J, Martin M, Calvo-Crespo P, et al. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society). Lung Cancer [Internet]. 2018 Apr [cited 2019 Feb 21];118:119–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29571989

9.         van Meerbeeck JP, Kramer GWPM, Van Schil PEY, Legrand C, Smit EF, Schramel F, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst [Internet]. 2007 Mar 21 [cited 2016 Jul 20];99(6):442–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17374834

10.      Eberhardt WEE, Pöttgen C, Gauler TC, Friedel G, Veit S, Heinrich V, et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol [Internet]. 2015 Dec 10 [cited 2016 Jul 20];33(35):4194–201. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26527789

11.      Pless M, Stupp R, Ris H, Stahel RA, Weder W, Thierstein S, et al. 1195OFINAL RESULTS OF THE SAKK 16/00 TRIAL: A RANDOMIZED PHASE III TRIAL COMPARING NEOADJUVANT CHEMORADIATION TO CHEMOTHERAPY ALONE IN STAGE IIIA/N2 NON-SMALL CELL LUNG CANCER (NSCLC). Ann Oncol. Oxford University Press; 2014;25(suppl 4):iv417-iv417.

12.      Shah AA, Berry MF, Tzao C, Gandhi M, Worni M, Pietrobon R, et al. Induction Chemoradiation Is Not Superior to Induction Chemotherapy Alone in Stage IIIA Lung Cancer. Ann Thorac Surg [Internet]. 2012 Jun [cited 2017 Nov 1];93(6):1807–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22632486

13.      Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, et al. Etoposide and Cisplatin vs Paclitaxel and Carboplatin With Concurrent Thoracic Radiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: A Multicenter Randomized Phase III Trial. Ann Oncol [Internet]. 2017 Jan 30 [cited 2019 Feb 11];28(4):mdx009. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28137739

14.      Senan S, Brade A, Wang L-H, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol [Internet]. 2016 Mar 20 [cited 2016 Jul 21];34(9):953–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26811519

15.      Yuan S, Sun X, Li M, Yu J, Ren R, Yu Y, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol [Internet]. 2007 Jun [cited 2016 Jul 21];30(3):239–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17551299

16.      Chen M, Bao Y, Ma H-L, Hu X, Wang J, Wang Y, et al. Involved-field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non-small cell lung cancer: a prospective randomized study. Biomed Res Int [Internet]. Hindawi Publishing Corporation; 2013 [cited 2016 Sep 4];2013:371819. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23762840

17.      Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-Field Radiation Therapy for Inoperable Non Small-Cell Lung Cancer. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2007 Nov 5 [cited 2016 Sep 5];25(35):5557–61. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2007.13.2191

18.      Senan S, Burgers S, Samson MJ, Klaveren RJ Van, Van J, De Koste S, et al. CAN ELECTIVE NODAL IRRADIATION BE OMITTED IN STAGE III NON–SMALL-CELL LUNG CANCER? ANALYSIS OF RECURRENCES IN A PHASE II STUDY OF INDUCTION CHEMOTHERAPY AND INVOLVED-FIELD RADIOTHERAPY.

19.      Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pöttgen C, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol [Internet]. 2018 Apr [cited 2019 Feb 18];127(1):1–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0167814018301154

20.      RTOG > Core Lab > Contouring Atlases > Lung Atlas [Internet]. [cited 2019 Feb 25]. Available from: https://www.rtog.org/CoreLab/ContouringAtlases/LungAtlas.aspx

21.      PhD, Feng-Ming, (Spring), Kong MD, MD, Leslie Quint, MD, Mitchell Machtay, MD JB. Atlases for Organs at Risk (OARs) in Thoracic Radiation Therapy [Internet]. Available from: https://www.rtog.org/CoreLab/ContouringAtlases.aspx

22.      Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr C. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p. Lancet Oncol. 2015;16(2):187–99.

23.      Ramroth J, Cutter DJ, Darby SC, Higgins GS, McGale P, Partridge M, et al. Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials. Int J Radiat Oncol Biol Phys [Internet]. 2016 Jul 25 [cited 2016 Sep 25]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27639294

24.      Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol [Internet]. 2017 Jan [cited 2019 Feb 11];35(1):56–62. Available from: http://ascopubs.org/doi/10.1200/JCO.2016.69.1378

25.      Liao ZX, Komaki RR, Thames HD, Liu HH, Tucker SL, Mohan R, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys [Internet]. 2010 Mar 1 [cited 2019 Feb 21];76(3):775–81. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301609003228

26.      Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med [Internet]. 2018 Dec 13 [cited 2019 Feb 11];379(24):2342–50. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1809697

27.      Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, et al. Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial. Int J Radiat Oncol [Internet]. Elsevier; 2018 Dec 1 [cited 2019 Feb 22];102(5):1604. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301618336927

28.      Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial. Int J Radiat Oncol [Internet]. Elsevier; 2018 Nov 1 [cited 2019 Feb 22];102(3):S3–4. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301618311064

29.      Robson JM, Vaidyanathan S, Cheyne L, Snee M, Franks K, Callister MEJ. Occult nodal disease in patients with non-small-cell lung cancer who are suitable for stereotactic ablative body radiation. Clin Lung Cancer [Internet]. 2014 Nov [cited 2019 Feb 19];15(6):466–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S152573041400148X

30.      Wood DE, Chair V, Aisner DL, Akerley W, Bauman J, Bruno D, et al. NCCN Guidelines Version 3.2019 Non-Small Cell Lung Cancer [Internet]. 2019 [cited 2019 Feb 19]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

31.      P. E. Postmus, K. M. Kerr, M. Oudkerk, S. Senan, D. A. Waller, J. Vansteenkiste, C. Escriu & S. Peters7  on behalf of the EGC. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2017 [cited 2019 Feb 4];4. Available from: https://watermark.silverchair.com/mdx222.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAlEwggJNBgkqhkiG9w0BBwagggI-MIICOgIBADCCAjMGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMQMcsQOcqY5Hvyu1cAgEQgIICBEkP_4lGyRo-tcuz2YWOuw_q5AS3gca-cs1csbEYI6WBA5m0

32.      Silvestri GA, Gonzalez A V, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest [Internet]. 2013 May [cited 2016 Jun 25];143(5 Suppl):e211S–50S. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23649440

33.      Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol [Internet]. 2019 Jan 17 [cited 2019 Feb 19];21(1):3–17. Available from: http://link.springer.com/10.1007/s12094-018-1978-1

34.      Pignon J-P, Tribodet H, Scagliotti G V, Douillard J-Y, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol [Internet]. 2008 Jul 20 [cited 2016 Jul 20];26(21):3552–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18506026

35.      Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW, et al. Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. J Clin Oncol [Internet]. 2015 Sep 1 [cited 2016 Jul 19];33(25):2727–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26101240

36.      Douillard J-Y, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe M-A, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized . Int J Radiat Oncol Biol Phys [Internet]. 2008 Nov 1 [cited 2016 Sep 25];72(3):695–701. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18439766

37.      Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol [Internet]. 2006 Jul 1 [cited 2016 Jul 20];24(19):2998–3006. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16769986

38.      Burdett S, Rydzewska L, Tierney JF, Fisher DJ, PORT Meta-analysis Trialist Group. A closer look at the effects of postoperative radiotherapy by stage and nodal status: updated results of an individual participant data meta-analysis in non-small-cell lung cancer. Lung Cancer [Internet]. 2013 Jun [cited 2019 Feb 21];80(3):350–2. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0169500213000640

39.      Billiet C, Decaluwé H, Peeters S, Vansteenkiste J, Dooms C, Haustermans K, et al. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: A meta-analysis. Radiother Oncol [Internet]. 2014 Jan [cited 2019 Feb 21];110(1):3–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24100149

40.      Mikell JL, Gillespie TW, Hall WA, Nickleach DC, Liu Y, Lipscomb J, et al. Postoperative Radiotherapy is Associated with Better Survival in Non–Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the National Cancer Data Base. J Thorac Oncol [Internet]. 2015 Mar [cited 2019 Feb 21];10(3):462–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25384064

41.      Gómez A, González JA, Couñago F, Vallejo C, Casas F, de Dios NR. Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clin Transl Oncol [Internet]. 2016 Apr 18 [cited 2019 Feb 19];18(4):331–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26280402

42.      Lynch R, Pitson G, Ball D, Claude L, Sarrut D. Computed tomographic atlas for the new international lymph node map for lung cancer: A radiation oncologist perspective. Pract Radiat Oncol [Internet]. 2013 Jan [cited 2019 Feb 18];3(1):54–66.

​

BIBLIOGRAFÍA DE PULMÓN - CASO CLÍNICO 3

​

(1)(Naruke T, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 96: 440-447, 1988)

(2)Raz DJ, et al. Natural history of stage I non-small cell lung cancer: implication for early detection. Chest 2007; 132: 193-199)

(3) Wisnivesky JP, el al. Radiation therapy for the treatment of unresected stage I-II non small cell lung cancer. Chest 2005; 128: 1461-1467).

(4)Timmerman R, et al. Extracranial estereotactic radioablation: results of a phase I study in medically inoperable stage I no small cell lung cancer. Chest 2003; 124: 1946-1955)

(5) Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomized trials. Lancet Oncol. 2015;16:630-7.

(6) Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101:1623–31)

(7) Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24 4833– 4839.

(8)  Lagerwaard FJ. El al. Outcomes of risk- adapted fractionated stereotactic radiotherapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 70. 3: 685-692.)

(9) Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–1076.

(10) Xiao Y, Papiez L, Paulus R, Timmerman R, Straube WL, Bosch WR, Michalski J, Galvin JM.Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009; 73: 1235-1242.

(11)Timmerman RD, Hu C, et al. Long-term results of RTOG 0236: A phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Medically Inoperable Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2014; 90:S30.

(12)Timmerman RD, Hu C, Michalski JM, et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer. JAMA Oncol 2018. [Epub ahead of print].

(13)Sun B, Brooks ED, Komaki RU, et al. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer 2017;123:3031-9

(14)Shibamoto Y, Hashizume C, Baba F, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol 2015;10:960-4.

(15) Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan clinical oncology group study JCOG0403. Int J Radiat Oncol Biol Phys 2015;93:989-96

(16) Videtic GM, Hu C, Singh AK, et al. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys 2015;93:757-64.

(17) Bezjak A, Paulus R, Gasper LE, et al. Efficacy and toxicity analysis of NRG oncology/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2016;96:S8.

(18) Chang, Poon, et al.The safety and effectiveness of stereotactic body radiotherapy for central verus ultracentral ling tumors. Radiat Oncol. 2018; 129: 277-283.

(19) Stanic S, et al. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early-stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys, 88 (5):1092-­‐99, 2014.

(20) Henderson M, et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing Stereotactic body radiotherapy for the treatment of stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 72 (2):404-09, 2008.

(21) Takeda et al. Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: comparison with non-small-cell lung cancer.Lung Cancer. 2012 Jul;77(1):77-82.

(22) Herder GJ, Van TH, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest. 2005; 128: 2490-2496.

(23) Coen W Hurkmans et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiation Oncology 2009, 4:1. disponible en http://www.rojournal.com/content/4/1/1.

(24) G.C. Hanna, et al. UK Consensus o Normal Tissue Dose Constraints for Stereotactic Radiotherapy. Clinical Oncology. 2018; 30:5-14.

(25)  Matsuo Y, Nakamoto Y, Nagata Y, et al. Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol. 2010;97:200–204.

(26) Zhang X, Liu H, Balter P, et al. Postiron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012;83:1558-65. 10.1016/j.ijrobp.2011.10.035

(27) Nguyen TK, Senan S, Bradley JD, et al. Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus Study. Pract Radiat Oncol 2018;8:e71-e78.

​

BIBLIOGRAFÍA PULMÓN - CASO CLÍNICO 4

​

1.Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890–895, 1992.

 2.Pignon J-P, Arriagada R, Ihde D, et al. A meta-analysis of thoracic ra- diotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-24.

 3.Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265–71.

 4.Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017; 18:1116.

 5.Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004; 22:4837.

 6.De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24:1057.

 7.Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341:476.

 8.Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009; 10:467.

​

​